MDB — Medicofarma Biotech SA Income Statement
0.000.00%
- PLN32.77m
- PLN32.71m
- PLN0.75m
Annual income statement for Medicofarma Biotech SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | PAS | PAS | PAS | PAS | PAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.18 | 3.65 | 3.34 | 4.25 | 0.751 |
Cost of Revenue | |||||
Gross Profit | 0.826 | 0.776 | 1.39 | 1.06 | 0.491 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.55 | 4.25 | 3.55 | 5.83 | 4.22 |
Operating Profit | -0.369 | -0.596 | -0.218 | -1.58 | -3.47 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.345 | -0.895 | -0.215 | -1.59 | -3.65 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.345 | -0.916 | -0.215 | -1.59 | -3.44 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.345 | -0.916 | -0.215 | -1.59 | -3.44 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.345 | -0.916 | -0.215 | -1.59 | -3.44 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.051 | -0.136 | -0.004 | -0.023 | -0.051 |
Dividends per Share |